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Abstract
Background: Increased cyclooxygenase activity promotes progression of colorectal cancer, but the mechanisms
behind COX-2 induction remain elusive. This study was therefore aimed to define external cell signaling and
transcription factors relating to high COX-2 expression in colon cancer tissue.
Method: Tumor and normal colon tissue were collected at primary curative operation in 48 unselected patients.
COX-2 expression in tumor and normal colon tissue was quantified including microarray analyses on tumor mRNA
accounting for high and low tumor COX-2 expression. Cross hybridization was performed between tumor and
normal colon tissue. Methylation status of up-stream COX-2 promoter region was evaluated.
Results: Tumors with high COX-2 expression displayed large differences in gene expression compared to normal
colon. Numerous genes with altered expression appeared in tumors of high COX-2 expression compared to tumors
of low COX-2. COX-2 expression in normal colon was increased in patients with tumors of high COX-2 compared
to normal colon from patients with tumors of low COX-2. IL1b, IL6 and iNOS transcripts were up-regulated among
external cell signaling factors; nine transcription factors (ATF3, C/EBP, c-Fos, Fos-B, JDP2, JunB, c-Maf, NF-B, TCF4)
showed increased expression and 5 (AP-2, CBP, Elk-1, p53, PEA3) were decreased in tumors with high COX-2. The
promoter region of COX-2 gene did not show consistent methylation in tumor or normal colon tissue.
Conclusions: Transcription and external cell signaling factors are altered as covariates to COX-2 expression in colon
cancer tissue, but DNA methylation of the COX-2 promoter region was not a significant factor behind COX-2
expression in tumor and normal colon tissue.
Background
Colorectal cancer is common in Western countries with
unanimous findings that prostaglandins are important
for both carcinogenesis and progression [1-3]. It has
been repeatedly observed that Cyclooxygenase-1/-2 inhi-
bition attenuates appearance of epithelial cancer in
experimental models and in part also in patients. Both
primary and secondary prevention with cyclooxygenase
(COX) inhibitors demonstrate and confirm decreased
incidence of colorectal carcinoma in both retrospective
and randomized patient cohorts [4-7]. Thus, a large
number of observations emphasize that induced prosta-
glandin production, particularly PGE2, is involved in cell
signaling through prostanoid receptors, where our own
observations suggested subtype EP2 receptor expression
in colon cancer tissue to predict reduced survival [2].
An important issue behind the appearance and progres-
sion of colorectal cancer seems to be increased produc-
tion of PGE2 secondary to COX-2 induction in both
transformed epithelial cells and host stroma [2,4,8-11].
Mechanisms behind COX-2 gene induction in colorectal
cancer disease remain elusive, although a lot of informa-
tion is available on the regulation of COX-2 gene
expression [12,13]. Most such information has, however,
been obtained in isolated cell culture experiments with
obvious limitations compared to the in vivo situation
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Therefore, the aim of the present study was to relate
well-recognized external cell- and transcription factor
expression to elevated tumor COX-2 expression in col-
orectal cancer tissue at primary operations aimed at
cure.
Methods
Patients
Tumor and colon tissue samples were collected from
48 unselected patients at primary operation for color-
ectal carcinoma between 2001 to 2004 in Uddevalla
county of Sweden. All patients underwent surgery as
t h eo n l yc u r a t i v et r e a t m e n ta n dn o n er e c e i v e dn e o a d -
juvant radio-chemotherapy, according to individual
decisions and institutional indications. Normal colon
tissue was collected as a minimum of 10 cm away
from the macroscopically seen tumor tissue. The
group of patients consisted of 54% males and 46%
females with a mean age of 72.5 years (range 40 to 91
years) at surgery. Mean survival time was 27.3 ± 4.2
months (range 0 to 73 months) following surgery
according to a recent update of survival (Dec 2008),
where 21 patients were still alive. Tumors were histo-
logically classified as Dukes A (8), Dukes B (19), Dukes
C (11) and Dukes D (10). PCR analysis was performed
to quantify COX-2 mRNA expression [2]. Mean COX-
2e x p r e s s i o ni nt u m o rt i s s u ef o rt h ee n t i r eg r o u pw a s
6.27 ± 0.60 mol/mol GAPDH (range 0.11 to 24.67) (n
= 48) and 14.6 ± 1.7 (range 1.7 to 38.08) (n = 29) in
normal colon tissue. Patients used in subsequent
experiments were selected according to COX-2 expres-
sion in tumors; one group of 10 patients with highest
and one group of 10 patients with lowest COX-2
expression (Figure 1, Table 1).
RNA and DNA extraction
Tumor and normal colon tissue samples were collected
down to the serosa layer during surgery and kept fresh
frozen in liquid nitrogen and stored in -80°C until analy-
sis. Certified pathologists staged all tumors. Tumor sam-
ples were secured by the surgeon in charge and
contained around 55-75% tumor cells according to ran-
dom visual inspection. RNA extraction and cDNA
synthesis were performed as described [2]. A quality
check of RNA in all samples was done in Bioanalyzer
2100 with limit RIN 6.0 for further analysis (Agilent).
DNA was extracted with QIAamp
® DNA Mini Kit (Qia-
gen) according to instructions. RNase A solution (Pro-
mega) was used as extra step in DNA purification.
Concentration of RNA and DNA was determined in
NanoDrop
® ND-1000 Spectrophotometer (NanoDrop
Technologies).
Gene expression analysis
Microarray analysis was performed on pooled tumor
mRNA from 9 out of 10 patients with high COX-2
mRNA expression versus 9 out of 10 patients with low
COX-2 mRNA expression. The two patients were
excluded due to low RIN indicating poor RNA quality.
500 ng of mRNA from tumors with high COX-2
patients was labeled with Cy-3-dCTP (Amersham BioS-
ciences) in a cDNA synthesis reaction with Agilent
Flourescent Direct Label. Tumor samples with low
COX-2 expression (500 ng) were labeled with Cy-5-
dCTP. Pooled tumor cDNA from patients with high
COX-2 versus pooled DNA from patients with low
COX-2 expression were then hybridized on whole
human oligo genome microarrays (4 × 44K expression
arrays, Agilent) during 18 hrs followed by post-hybridi-
zation washes according to in situ instructions (Hybridi-
zation Kit Plus, Agilent). Microarrays were quantified on
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Figure 1 Distribution of COX-2 among patients (n = 48). COX-2
expressions of tumors used in this study were distributed at the top
and bottom quartile.
Table 1 Classification of patients with high or low COX-2
expression in tumor tissue
COX-2 expression in tumor tissue
High (10) Low (10)
COX-2 T 12.5 ± 1.5 2.6 ± 0.4
(mol/mol GAPDH) NM 5.06 ± 3.0 12.3 ± 4.0
Dukes
1 3A ,6B ,1D 3B ,5C ,2D
Age at surgery 71 ± 2.5 73 ± 3.4
Gender 6 M, 4 F 4 M, 6 F
Postoperative survival (months) 23 ± 5.8 29 ± 8.0
Right/left colon 4/6 4/6
Mean ± SEM.
T = tumor tissue.
NM = Normal colon tissue.
1Approx. TNM; A = T1, N0, M0; B = T2/T3, N0, M0; C = T2/T3/T4, N1/N2, M0;
D = T2/T3/T4, N1/N2, M1.
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Page 2 of 10Agilent G2565 AA microarray scanner and data were
pre-processed in Feature Extraction 9.1 software pro-
gram (Agilent). The same procedures were performed
with normal colon mucosa tissue from all patients with
only 4 patients per pool due to poor RNA quality. One
hybridization with high COX-2 tumor expression versus
corresponding normal colon mucosa tissue was also per-
formed. Four technical replicates of all tumor tissue ana-
lyses and two technical replicates of normal colon tissue
and tumor versus normal colon tissue analyses were per-
formed. Dye-normalized, outlier- and background sub-
tracted values were analyzed in GeneSpring GX 10
software program (Agilent) according to standard proce-
dures. A quality control was performed with QC metrics.
Analysis used were filter on flags (present or marginal)
were 27194 probes (out of 41078) passed in 2 out of 4
technical replicates with tumor tissue. In normal tissue
25735 probes passed and in tumor vs normal tissue 27919
probes passed filter on flags for further analysis with t-test
(p < 0.05). Fold change 1.5 of log2 transformed ratios was
considered a statistically significant change in gene expres-
sion. Significant pathway analysis with entity list FC 1.5
was used to define significantly altered pathways. PCR
analyses were performed at Tataa Biocenter (Gothenburg,
Sweden) in a LightCycler 480 Probe Master (Roche). PCR
assays (AKT1 HS00178289_m1, IL1B HS01555410_m1,
IL6 HS00985639_m1, TRA@ HS 00612292_m1, CARD11
HS01060626_m1, Applied Biosystems) were tested and
validated for efficiency and specificity. All samples were
run in duplicate and negative controls were negative.
Results were related to assay efficiency and GAPDH
(GAPDH assay from Tataa Biocenter’s Reference Gene
Panel Human) and calculated according to comparative Ct
method.
DNA methylation analysis with bisulfite sequencing
Methylation analysis was performed with tag-modified
bisulfite genomic sequencing [14]. EpiTect
® Bisulfite kit
(Qiagen) was used for bisulphite modification of 1 μg
tumor and normal colon tissue DNA from each patient
(n = 20) according to instructions. Modified DNA sam-
ples were amplified with two different sets of primers
(Table 2) directed towards two areas of the COX-2 pro-
moter region using touchdown PCR (1 × Reaction Buffer,
0.5 mM dNTPs, 2.0 mM MgCl2,0 . 4μMf o r w a r da n d
reverse primers resp., and 1 unit HotStart Taq (Qiagen).
Primer pair 1 was taken from Hur et al. and primer pair
2 was designed with BiSearch [15,16]. PCR reactions
were denatured at 95°C for 10 min, then 20 cycles of 95°
C 45 s, 60°C/65°C annealing temperature with a decrease
of half a degree per cycle for 45 s, 68°C 60 s followed by
15-20 cycles of 95°C 45 s, 50°C/55°C 45 s and 68°C 60 s
ended with a 7 min extension at 68°C. EpiTect
® PCR
Controls (Qiagen) was used to ensure that the reaction
worked properly; one methylated control sample, one
unmethylated control and a 50/50 mixture of methylated
and unmethylated controls were included in each PCR to
ensure that methylated and unmethylated template were
both equally amplified. The specificity of PCR products
was inspected by use of 2100 Bioanalyzer according to
protocol for DNA 1000 (Agilent). PCR products were
then purified using Agencourt AMPure magnetic beads
(Agencourt Bioscience Corporation) using the Biomek
NX pipetting robot (Beckman Coulter) and eluted in dis-
tilled water. Sequence PCR was performed using forward
or reverse primer with the ABI Prism BigDye™ cycle
sequencing Ready Reaction Kit v1.1 (Applied Biosys-
tems). Sequence PCR was run in 10 μl reactions under
following conditions: 96°C 1 min, followed by 25 cycles
of 96°C 10 s and 50°C 4 min. Sequencing products were
purified using CleanSeq magnetic beads (Agencourt)
using the Biomek NX and re-suspended in 10 μlo fH i g h
Dye formamide (Applied Biosystems). The sequencing
products were separated with gel electrophoresis on a
3730 DNA analyser (Applied Biosystems) and the output
data were viewed and analysed using Sequence Analysis
v5.2 (Applied Biosystems) and BiqAnalyzer [17].
Statistics
Results are presented as mean ± SEM. Statistical ana-
lyses were performed by ANOVA and p < 0.05 was
regarded significant in two-tailed tests. This study was
approved by the board of Ethics at University of
Gothenburg (NCT00473980). Accordingly, all patients
participated with informed consent.
Results
COX-2 expression
L a r g ed i f f e r e n c ei ng e n ee x p r e s s i o nw a so b s e r v e dw h e n
comparing tumor tissue with high COX-2 expression to
normal colon mucosa tissue from the same patients
(2557↑,3 1 8 2 ↓) (Table 3). A large number of genes with
Table 2 Primers used for methylation analysis
Tag Primer Sequence (5’-3’)B p
1 FP1692 CCACTCACTCACCCACCCGAAGAAGAAAAGATATTTGG 448
1 RP2104 GGGTGGGAGGTGGGAGGGATAAACTTTACTATCTAAAA
2 B1(1595) CCACTCACTCACCCACCCTTGGAGAGGAAGTTAAGTGTTT 223
2 b1(1782) GGGTGGGAGGTGGGAGGGATCCCCACTCTCCTATCTAAT
Asting et al. BMC Cancer 2011, 11:238
http://www.biomedcentral.com/1471-2407/11/238
Page 3 of 10altered expression appeared also in colon cancer tissue
of tumors with high COX-2 expression when compared
to tumors with low COX-2 expression (3086↑, 3031↓)
(Table 4). Expression of COX-2 in normal colon mucosa
tissue was significantly increased in patients with tumors
of high COX-2 expression compared with mucosa from
patients with low COX-2 expression in tumors (776↑,
804↓). Highly expressed genes in tumor tissue with high
COX-2 expression were associated to cell motility, cell
structure, muscle proteins, and energy homeostasis
while down-regulated genes in such tumors seemed to
be related to tumor antigens as Melanoma antigen and
Chondrosarcoma ass. Gene, etc (Table 4). Several factors
of immune response as serpin peptidase inhibitor and
inducible metric oxide synthase 2 with antitumoral
activities were either up- or down-regulated in normal
colon tissue from patients with tumors of high COX-2
expression (Table 5). Patien t sw i t ht u m o r sw i t hh i g h
COX-2 expression did not in the present material dis-
play significantly reduced survival compared to patients
with tumors with low COX-2 expression (Table 1).
However, COX-2 expression predicted survival at bor-
derline significance in a larger patient material [2].
Transcription factors
A large number of transcription factors with reported
importance for regulation of the COX-2 gene in human
cells were evaluated and are listed in Table 6. Eight of
these transcription factors showed increased expression,
while 5 transcription factors were down-regulated in
tumors with high COX-2 expression.
External factors
Genes with reported functions in external cell signaling
indicated 6 genes with increased expression, while no
gene indicated down-regulation related to high COX-2
Table 3 Genes listed according to the magnitude of most altered expression between tumor tissue and normal
mucosa from the same patients with tumors of high intrinsic COX-2 expression
Gene ↑/↓ FC Function Gene Symbol
(GeneID)
Matrix metallopeptidase 7 ↑ 110 Breakdown of extracellular matrix, metastasis MMP7 (4316)
Keratin 23 ↑ 77 Structural integrity of epithelial cells KRT23 (25984)
Myosin ↑ 63 Muscle, heavy polypeptide 2 MYH2 (4620)
Claudin 1 ↑ 38 Integral membrane protein, component of tight junction strands CLDN1 (9076)
Actin a1, skeletal ↑ 36 Cell motility, structure and integrity ACTA1 (58)
Forkhead box Q1 ↑ 34 Transcription factor (i.e. TGF-beta2) FOXQ1 (94234)
Proprotein convertase subtilisin/
kexin type 1
↑ 22 Regulating insulin biosynthesis, obesity, activate precursor protein, associated with
carcinoid tumors
PCSK1 (5122)
Sarcolipin ↑ 25 Regulates several sarcoplasmic reticulum Ca(2+)-ATPases SLN (6588)
Matrix metallopeptidase 1 ↑ 14 Breakdown of extracellular matrix, metastasis MMP1 (4312)
Myosin, cardiac, beta ↑ 25 Heavy chain, also expressed in skeletal muscle tissues rich in slow-twitch type I
muscle fibers
MYH7 (4625)
Hydroxy-δ-5-steroid
dehydrogenase
↓ 79 Biosynthesis of steroid hormones, polymorphisms related to prostate cancer HSD3B2 (3284)
Hydroxy-δ-5-steroid
dehydrogenase
↓ 30 Biosynthesis of steroid hormones, diagnostic trophoblastic marker HSD3B1 (3283)
similar to 3 b-hydroxysteroid
dehydrogenase
↓ 28 Pseudogene LOC391081
(391081)
- ↓ 24 unknown CR627415
Butyrylcholinesterase ↓ 21 Homozygoutics sustain prolonged apnea after administration of the muscle relaxant
suxamethonium
BCHE (590)
Neuronal pentraxin ↓ 19 Excitatory synapse remodelling, mediate neuronal death induced by reduction in
neuronal activity in mature neurons
NPTX1 (4884)
Dipeptidyl-peptidase 6 ↓ 18 Binds and alters specific voltage-gated potassium channels expression and
biophysical properties
DPP6 (1804)
ATP-binding cassette, sub-family
G
↓ 17 Breast cancer resistance protein, xenobiotic transporter may play a major role in
multi-drug resistance
ABCG2 (9429)
Insulin like-5 ↓ 17 Relaxin/Insulin family, ligand for GPCR142 INSL5 (10022)
Regenerating islet-derived 1 b ↓ 16 Highly similar to REG1A protein (islet cell regeneration and diabetogenesis) REG1B (5968)
↑ increased expression.
↓ decreased expression.
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Page 4 of 10expression in tumor tissue (Table 7). Table 8 describes
genes with significantly altered expression of transcrip-
tion factors and external cell signaling factors in normal
mucosa from patients with tumors of increased COX-2
expression. IL1-b,I L 6 ,a n di N O Sw e r eu p - r e g u l a t e d ,
probably inducing a variety of transcription factors.
Pathway analysis
Significantly altered metabolic and signaling pathways
( F C1 . 5 )i nt u m o r sw i t hh i g hC O X - 2e x p r e s s i o nw e r e
mainly related to immunity according to algorithm ana-
lyses (GeneSpring GX 10, Agilent). Five genes that were
significantly changed in arrays (AKT1, CARD11, IL1B,
IL6, and TRA@) and involved in significantly changed
pathways according to the algorithm analyses (TCR,
BCR, IL1, and IL6) were tested individually (Table 9).
All results from individual PCR analyses agreed with
array results with one exception; in tumor tissue with
high compared to low COX-2 expression AKT1 expres-
sion was significantly higher in PCR analyses, with
opposite direction in array analysis.
DNA methylation
A majority of tumor tissue specimens displayed no
methylation of the promoter region of the COX-2 gene
in tumor tissue; only 2 tumors showed methylation of
the promoter region (low COX-2, Dukes B tumors with
intermediate differentiation). Methylation of the promo-
ter region of the COX-2 gene was not observed in any
of the normal colon mucosa specimens.
Discussion
Increased prostanoid activity is a well recognized char-
acteristic of colorectal cancer [4,8,10,18-20]. Early, it was
claimed that such tumors have increased COX-2 expres-
sion deduced from immunohistochemical evaluations of
tumor tissue specimens. More recent investigations have
however emphasized that increased COX-2 expression
in colorectal cancer is preferentially a local phenomenon
with uneven distribution among transformed cells with-
out overall increased tissue content [11]. These findings
imply heterogenous cell clones or that other factor are
responsible for either up- or down-regulation of COX-2
Table 4 Genes listed according to the magnitude of most altered expression in tumor tissue of high intrinsic COX-2
expression
Gene ↑/↓ FC Function Gene Symbol
(GeneID)
Unknown ↑ 156 unknown W60781
Myosin ↑ 107 Muscle, heavy polypeptide 2 MYH2 (4620)
Desmin ↑ 49 Muscle filament DES (1674)
Creatine kinase ↑ 46 Muscle, energy homeostasis, serum marker for myocardial infarction CKM (1158)
Troponin T type 3 ↑ 41 Skeletal TNNT3 (7140)
Actin a, cardiac ↑ 37 Muscle, contractile, cell motility ACTC1 (70)
Actin a1, skeletal ↑ 35 Cell motility, structure and integrity ACTA1 (58)
Synaptopodin 2 ↑ 28 Cell-shape regulation, homolog with Myopodin (a tumor suppressor; inhibits growth
and metastasis)
SYNPO2 (171024)
Nebulin ↑ 25 Cytoskeletal matrix NEB (4703)
Calponin ↑ 23 Differentiation marker, reduced in tumor vessels associated with tumor progression CNN1 (1264)
Growth diff. factor 10 ↓ 28 Regulation of cell growth and differentiation GDF10 (2662)
Unc-13 homolog A ↓ 19 diacylglycerol and phorbol ester receptors, essential role in synaptic vesicle priming UNC13A (23025)
LOC553137 ↓ 16 miscRNA, unknown function LOC553137
(553137)
Melanoma antigen family B,
2
↓ 14 Tumor-associated antigen, expressed only in testis and tumors, regulated by
demethylation
MAGEB2 (4113)
Chondrosarcoma associated
gene 1
↓ 13 Tumor antigen, expressed in testis and in chondrosarcomas CSAG1 (158511)
Folate receptor 1 ↓ 13 Involvement in cancer prognosis FOLR1 (2348)
Renin ↓ 13 Blood pressure and electrolyte balance REN (5972)
Small proline-rich protein 3 ↓ 12 Epithelial homeostatis, aberrant expression contribute to tumorigenesis of esophageal
squamous cell carcinoma
SPRR3 (6707)
Heat shock 27kDa protein 3 ↓ 12 Muscle HSPB3 (8988)
Chromogranin B ↓ 11 Precursor for biological active peptides, involved early in breast cancer CHGB (1114)
↑ increased expression.
↓ decreased expression.
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Page 5 of 10in malignant cells. It is also important to underline that
increased COX-2 expression in tumor tissue may well
be confined to stroma and host cells. Such a complex
condition supports cross-talk among cells with prosta-
noids as signals through specific receptors. Our previous
investigations have demonstrated a statistically signifi-
cant relationship between COX-2 expression and tumor
tissue production of PGE2, which is elevated in colon
cancer tissue [11]. These kinds of findings agree with
information that both primary and secondary interven-
tion with cyclooxygenase inhibitors influenced on both
local tumor growth and systemic effects in experimental
and clinical cancer [4]. Of particular interest may be
previous observations that subtype EP2 receptor expres-
sion in colon cancer tissue predicted reduced survival
[2]. Seen together, it seems that induction of COX-2 is
a key-factor behind progression of epithelial cell trans-
formation to invasive cancer in colon mucosa. This
logic has been practically explored evaluating the role of
COX-2 inhibition on epithelial dysplasia in esophageal
mucosa, although without consistent results [21]. How-
ever, understanding in part complex cell to cell interac-
tions and signaling in composed tissues it should not be
expected to be isolated single factors behind local and
systemic tumor progression. Therefore, we intended to
evaluate relationships between high COX-2 expression
in colon cancer tissue to other factors of known impor-
tance for tumor cell division, apoptosis, and metastasis.
In this perspective microarray screening should be
rewarding.
With this purpose we have quantified COX-2 expres-
sion in primary tumors from 48 unselected patients with
Table 5 Genes listed according to the magnitude of most altered expression in normal mucosa from patients with
tumors of high intrinsic COX-2 expression
Gene ↑/↓ FC Function Gene Symbol
(GeneID)
Pancreatic derived factor
(PANDER)
↑ 79 Cytokine, induces apoptosis of alpha and beta cells, implicated in diabetes FAM3B (54097)
Regenerating islet-derived 1
a
↑ 40 Secreted by the exocrine pancreas, associated with islet cell regeneration and
diabetogenesis
REG1A (5967)
Ribosomal protein S4, Y-
linked 2
↑ 40 Translation RPS4Y2
(140032)
Serpin peptidase inhibitor,
ovalbumin
↑ 35 Cytoprotective, cell survival factor, monocyte regulation, potential cancer marker (elevated
in plasma)
SERPINB2
(5055)
Nitric oxide synthase 2,
inducible
↑ 19 reactive free radical, biologic mediator in several processes, incl. neurotransmission,
antimicrobial and antitumoral activities
NOS2A (4843)
Pentraxin-related gene ↑ 16 Immune response, inflammation, rapidly induced by IL-1b PTX3 (5806)
Regenerating islet-derived 1
b
↑ 16 highly similar to REG1A protein REG1B (5968)
Hydroxy-delta-5-steroid
dehydrogenase
↑ 10 Biosynthesis of steroid hormones, polymorphisms related to prostate cancer HSD3B2 (3284)
Hydroxy-delta-5-steroid
dehydrogenase
↑ 10 Biosynthesis of steroid hormones, diagnostic trophoblastic marker HSD3B1 (3283)
ADAM metallopeptidase ↑ 10 cleavage of proteoglycans, control of organ shape during development, and inhibition of
angiogenesis
ADAMTS9
(56999)
Unknown ↓ 15 unknown ENST00000343
6-phosphofructo-2-kinase ↓ 13 Produce fructose 2,6-P(2), involved in Warburg effect PFKFB3 (5209)
hemoglobin, g A ↓ 8 Normally expressed in the fetal liver, spleen and bone marrow HBG1 (3047)
matrix metallopeptidase 7 ↓ 8 Breakdown of extracellular matrix, metastasis MMP7 (4316)
Fc receptor-like 4 ↓ 7 Immune regulation FCRL4 (83417)
Chemokine receptor 5 ↓ 6 B cell migration and localization BLR1 (643)
Fibroblast growth factor 5 ↓ 6 Mitogenic and cell survival activities, involved in a variety of biological processes, incl. cell
growth, morphogenesis, tissue repair, tumor growth and invasion, oncogene
FGF5 (2250)
Family with sequence
similarity 129, member C
↓ 6 B-cell novel protein, BCNP1 completely unknown protein with 3 predicted transmembrane
domains
FAM129C
(199786)
selectin L ↓ 6 Leukocyte-endothelial cell interactions SELL (6402)
Zinc finger protein ↓ 5 DNA binding ZNF683
(257101)
↑ increased expression.
↓ decreased expression.
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Page 6 of 10R0 resected primary tumors. Then, tumor tissue with 10
highest and lowest COX-2 expressions was chosen for
subsequent hybridization in various combinations. Such
cross-combinations of tissues for microarray expression
analyses revealed that tumors with high intrinsic COX-2
expression displayed pronounced up-regulation of genes
related to muscle fibers and cytoskeleton matrix, per-
haps reflecting matrix remodeling including angiogen-
esis. By contrast, down-regulated genes in such tumors
were more related to functional proteins and eventual
cellular antigens (Table 4). Similar findings were
Table 6 Significant alterations in expression of previously
reported important transcription factors in tumors of
high intrinsic COX-2 expression
Gene Product FC 1.5 FC 2.0 FC 3.0 Reference
a
TFAP2C AP-2g ↓ - - [12]
TFAP2E AP-2ε --- [12]
ATF1 ATF1 --- [13]
ATF2 ATF2/CREB2 --- [13]
ATF3 ATF3/AP1 ↑ - - [13]
BATF B-ATF --- [13]
CREBBP CBP/p300 co-activator --- [12]
CDX2 CDX2 ↓ - - [29]
CEBPA C/EBP-a --- [13]
CEBPB C/EBP-b --- [13]
CEBPD C/EBP-δ ↑↑- [13]
CREB5 CRE-BPA --- [13]
CREB1 CREB --- [13]
ELK1 Elk-1 ↓ - - [13]
FOS c-Fos/AP1 ↑ - - [12]
FOSB Fos-B/AP1 ↑↑↑ [12]
FOSL1 Fra-1/AP1 --- [12]
FOSL2 Fra-2/AP1 --- [12]
DNAJC12 JDP1 --- [12]
JDP2 JDP2 ↑ - - [12]
JUN Jun/AP1 --- [12]
JUNB JunB/AP1 --- [12]
JUND JunD/AP1 ↑ - - [12]
MAF c-Maf/AP1 ↑↑- [12]
NFATC1 NFATc1/NFAT2 --- [12]
NFATC4 NFAT3 --- [12]
NFATC3 NFAT4 --- [12]
NFAT5 NFAT5 --- [12]
NFKB1 NF-B, p105/p50 --- [12,13]
NFKB2 NF-B, p100 --- [12,13]
RELA NF-B, RelA (p65) --- [12,13]
RELB NF-B, RelB --- [12,13]
REL NF-B, c-Rel --- [12,13]
NFKBIA NF-B, IBa ↑↑- [12,13]
NFKBIB NF-B, IBb --- [12,13]
NFKBIE NF-B, IBε --- [12,13]
CHUK NF-B, IKK-a --- [12,13]
IKBKB NF-B, IKK-b --- [12,13]
IKBKG NF-B, IKK-g --- [12,13]
TP53 p53 ↓↓- [30]
ETV4 PEA3 ↓ - - [13]
PPARA PPARa --- [12]
PPARD PPARb/δ --- [12]
PPARG PPARg --- [12]
SP1 SP-1 --- [12]
Table 6 Significant alterations in expression of previously
reported important transcription factors in tumors of
high intrinsic COX-2 expression (Continued)
TBP TATA-binding protein --- [12]
TCF4 TCF4 ↑↑- [13]
AP-2a, AP-2b, AP-2δ, NFAT1 and Retinoic acid receptor were also tested, but
no expression were found.
↑ increased expression; ↓ decreased expression; FC is log2 fold changes.
a published report with emphasis on transcription factor in regulation of
COX-2 gene.
Table 7 Significant alterations in expression of previously
reported important external cell signaling factors and
enzymes in tumors of high intrinsic COX-2 expression
Gene Product FC
1.5
FC
2.0
FC
3.0
Reference
a
DNMT1 DNA MTase 1 - - - [26]
DNMT3A DNA MTase 3A ↑↑- [26]
DNMT3B DNA MTase 3B - - - [26]
MDM2 hdm2 - - - [30]
HPGD HPGD - -- [ 1 ]
HNRPD HuR - - - [31]
IL1B IL1b ↑↑- [32,33]
IL6 IL6 ↑↑↑ [34]
IL6R IL6 receptor ↑ - - [34]
NOS2A iNOS - - - [13]
MAPK14 p38 MAPK - - - [35]
PTGES mPGES-1 - -- [ 1 ]
PRKCB1 Protein kinas Cb1 ↑↑↑ [12]
RALA Ras family (oncogene) - - - [12]
RASA4 Ras p21 protein
activator
- - - [12]
RASSF1 Ras ass. (tumor supr.) - - - [12]
RIN2 Ras and Rab interact. 2 - - - [12]
TINP1 TGF-b - - - [13]
TNF TNF-a ↑ - - [13]
↑ increased expression.
↓ decreased expression.
FC is log2 fold change.
a published report with emphasis on the current factors.
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mal mucosa from the corresponding patients (Table 3).
Most interesting was however, findings that normal
colon tissue from patients with high intrinsic COX-2
expression in tumor tissue revealed pronounced up- and
down-regulation of several gene functions. Such obser-
vations led to the conclusion that colon tissue in
patients with colon cancer is significantly altered in
regards to functional aspects either primarily or second-
ary to the appearance of manifest tumor. Analysis of sig-
nificantly altered pathways at high COX-2 displayed that
most alterations were related to immune reactions in
t h ep r e s e n ta n dp r e v i o u sa n a l y s e s[ 2 2 ] .T h i sc o n f i r m s
our previous results based on an alternative approach
where preoperative COX inhibition by indomethacin
mainly affected genes and pathways that involved the
immunity [22,23].
It may be rewarding to understand the control of
COX-2 gene expression behind complex in vivo interac-
tions as emphasized. According to this line we evaluated
a large number of proposed genes with importance for
COX-2 expression as listed in Table 6. Fourteen out of
47 genes were found to have significantly altered expres-
sion defined at least as 1.5 fold change compared to
normal mucosa or by chance variation in transcript
expression. Fos-B/AP1 expression displayed the most
pronounced alteration of up-regulated transcripts
among transcription factors. A transcription complex
known to regulate COX-2 gene expression via binding
to CRE-sites in the promoter region is Activator protein
1 (AP-1), which consists of homo- or heterodimers of
JUN- and FOS-families with roles in several different
cancers. In colorectal cancer AP-1 may be activated by
either K-RAS mutation or via Wnt signals. Different
genes are transcribed controlling biological activities
such as proliferation, apoptosis and differentiation
depending on the sub-components of AP-1 [24,25]. Six
of 19 factors with emphasized importance for external
cell signaling were up-regulated in tumor tissue of high
intrinsic COX-2 expression (Table 7). As expected, such
experiments confirmed no significant transcript with
decreased expression. IL6 and protein kinas Cb1
appeared most up-regulated in such cross hybridiza-
tions, although transcription of NF-B was not elevated.
In this context it is important to emphasize that protein
and gene activation may occur despite evidence of
unchanged transcription levels, usually subsequent to
phosphorylation changes. Again, it was observed that 9
transcription factors and IL1b, IL6 and iNOS were sig-
nificantly altered in normal colon tissue from patients
with tumors of high intrinsic COX-2 expression. Indivi-
dual confirmation of array results by PCR determina-
tions displayed also a significantly higher expression of
Table 8 Significant alterations in expression of
transcription factors and cell signaling factors in normal
colon mucosa from patients with tumors of high intrinsic
COX-2 expression
Gene Product FC 1.5 FC 2.0 FC 3.0
PTGS2 COX-2 ↑↑↑
Transcription
ATF3 ATF3/AP1 ↑ --
CEBPD C/EBP-δ ↑↑-
CREB1 CREB ↑ - -
FOSB Fos-B/AP1 ↑↑-
DNAJC12 JDP1 ↑ - -
NFATC1 NFATc1/NFAT2 ↓ --
PPARG PPARg ↓ --
BATF B-ATF ↓ --
External cell factors
IL1B IL1b ↑↑↑
IL6 IL6 ↑↑↑
NOS2A iNOS ↑↑↑
All factors listed in Table 6 and 7 were evaluated.
Table 9 Gene expressions in tumor tissue with high COX-2 expression compared to tumor tissue with low COX-2
expression confirmed by q-PCR
CARD 11 TRA@ IL6 IL1B AKT1
High
COX-2 (9)
Low
COX-2 (9)
High
COX-2 (9)
Low
COX-2 (9)
High
COX-2 (9)
Low
COX-2 (9)
High
COX-2 (9)
Low
COX-2 (9)
High
COX-2 (9)
Low
COX-2 (9)
Mean 0.40 ± 0.08 0.42 ± 0.24 2.87 ± 0.63 0.55 ± 0.14 1.97 ± 0.79 0.09 ± 0.03 1.61 ± 0.49 0.27 ± 0.06 1.09 ± 0.13 0.62 ± 0.07
Median 0.39 0.07 3.12 0.44 0.87 0.05 1.01 0.21 0.96 0.59
Variance 0.06 0.50 3.57 0.18 5.65 0.008 2.16 0.04 0.14 0.04
P-value* ns 0.002 0.03 0.02 0.005
*ANOVA analysis.
CARD11 = caspase recruitment domain family, member 11.
TRA@ = T cell receptor alpha locus.
IL6 = Interleukin 6.
IL1B = Interleukin 1b.
AKT1 = v-akt murine thymoma viral oncogene homolog 1 or protein kinase B.
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Page 8 of 10IL1b and IL6 at high COX-2. This phenomenon demon-
strates that overall COX-2 expression in primary color-
ectal carcinoma probably includes primary and
secondary alterations in tumor un-involved colon tissue.
It is well recognized that methylation of CpG island
located within promoter regions of genes may silence
gene expression, described as a hallmark in human can-
cer. This represents findings early during carcinogenesis
and is maintained by DNA methyltransferase (DNMTs)
[26]. Such methylation of the COX-2 promoter region
may be associated with loss of gene expression as
reported for gastric cancer [15,27]. Similar evidence has
been reported for COX-2 gene expression in colorectal
cancer [27,28], although, statistical evaluations of
reported observations do not give the impression that
COX-2 expression in colon cancer tissue is related to
COX-2 promoter methylation. Accordingly, we did not
observe significant methylation in two well-defined parts
of the COX-2 promoter region in tumor and normal
colon tissues. However, DNA methyltransferase was
expressed at increased levels in tumor tissue compared
to the corresponding normal colon tissue. Therefore, it
is unlikely that promoter methylation was a significant
factor behind the lack of COX-2 expression in presently
investigated areas of colon cancer tissue. It remains to
be determined how COX-2 is either induced in tumor
tissue with intrinsic high COX-2 expression or down-
regulated in tumor cells with correspondingly low over-
all COX-2 expression to provide the well-recognised
scattered pattern of expression observed in immunohis-
tochemical cross tissue sections. Important is our obser-
vation that COX-2 expression in normal colon tissue
was also significantly increased in patients with tumors
of high COX-2 expression. This points to the possibility,
that the mucosa or entire colon tissue may be altered as
a general phenomenon in patients with certain kind of
colon tumors. Perhaps, the inflammatory activation by
some kind of bacterial flora(s) could be a speculative
guess.
Conclusion
Our present study emphasized and confirmed our pre-
vious observations that increased COX-2 expression or
tissue content is overall not a unanimous finding in col-
orectal cancer tissue. A scattered presence of COX-2
may rather represent different cell clones or different
local conditions at the cellular level. Both transcription
and external cell signaling factors were significantly
altered as covariates to COX-2 expression in colon can-
cer tissue. DNA methylation of the COX-2 promoter
region did not seem to be a significant factor behind
COX-2 expression in either tumor tissue or normal
colon tissue in the present material. Our results confirm
that both local and systemic inflammation promote
tumor growth and disease progression.
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